Publications by authors named "David Batt"

Claim this Profile
A
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
Qing Sheng, Xinggang Liu, Eleanor Fleming, Karen Yuan, Huiying Piao, David Batt

Cancer Cell· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
Sven A Lang, Philipp Schachtschneider, Christian Moser, Akira Mori, Christina Hackl, David Batt

Mol Cancer Ther· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model.
Sven Arke Lang, Isabel Brecht, Christian Moser, Aiman Obed, David Batt

Langenbecks Arch Surg· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.
Anita B Hjelmeland, Kathryn P Lattimore, Brian E Fee, Qing Shi, Sarah Wickman, David Batt

Mol Cancer Ther· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-Raf kinase inhibitors for cancer treatment.
Nanxin Li, David Batt, Markus Warmuth

Curr Opin Investig Drugs· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Constantine S Mitsiades, Joseph Negri, Ciaran McMullan, Douglas W McMillin, Elias Sozopoulos, David Batt

Mol Cancer Ther· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
Sith Sathornsumetee, Anita B Hjelmeland, Stephen T Keir, Roger E McLendon, David Batt

Cancer Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Bin Ouyang, Jeffrey A Knauf, Eric P Smith, Lei Zhang, Tim Ramsey, David Batt

Clin Cancer Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis